课题基金 / 基金详情

The Role of Behavior Therapy Combined with Buprenorphine for the Treatment of Opioid Use Disorder

The Role of Behavior Therapy Combined with Buprenorphine for the Treatment of Opioid Use Disorder
行为疗法联合丁丙诺啡治疗阿片类药物使用障碍的作用
批准号:
10440820
负责人:
Rebecca Kathryn McHugh
金额:
$35.06万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
未结题
起止时间:
2022-05-01 至 2025-03-31

项目摘要

项目成果

Rebecca Kathryn McHugh的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Project Summary/Abstract The misuse of opioids has reached an epidemic level in the United States, with approximately 2 million people suffering from opioid use disorder and over 46,800 opioid overdose fatalities in 2019. Medication-based treatment for opioid use disorder—such as buprenorphine maintenance—is effective and can save lives, however, approximately half of people who receive buprenorphine do not adequately respond or drop out of treatment. In contrast to other substance use disorders, the addition of behavior therapy to buprenorphine has not consistently shown improvements in opioid use outcomes for opioid use disorder. Preliminary evidence suggests that not everyone may need the addition of behavior therapy to buprenorphine to reduce opioid use, but that certain subgroups of people may benefit from behavior therapy. The ability to understand heterogeneity in response to treatment for opioid use disorder is hampered by the need for very large sample sizes to test questions about moderators of treatment response. Understanding subgroup differences can ultimately inform personalized medicine approaches to the treatment of opioid use disorder. Our objective for this proposal is to answer urgent questions about subgroup responses to behavioral therapy by harmonizing data from 4 completed clinical trials of treatment for opioid use disorder. These NIDA-funded randomized trials each tested the efficacy of behavior therapy added to buprenorphine maintenance for opioid use disorder and include common data elements, allowing for their harmonization. Our project aims include: (1) to identify subgroups who respond to behavior therapy when added to buprenorphine maintenance for opioid use disorder, (2) to quantify the efficacy of behavior therapy for improving buprenorphine treatment retention, and (3) to quantify the efficacy of behavior therapy for functional outcomes. The results from this study will provide important information about who responds to behavior therapy and the effect of behavior therapy on non-opioid use endpoints. Our proposal will utilize well-validated longitudinal data analysis methods, including a rigorous approach to missing data. By using existing datasets, this proposal provides an efficient way to answer urgent questions about the treatment of opioid use disorder and provides significant added value to these trials. These findings can be immediately used to inform personalized approaches to treatment for opioid use disorder and will also contribute to understanding of the impact of behavior therapy on endpoints of interest to patients and families.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
The Role of Behavior Therapy Combined with Buprenorphine for the Treatment of Opioid Use Disorder
  • 批准号:
    10612103
  • 项目类别:
  • 资助金额:
    $35.06万
  • 财政年份:
    2022
  • 负责人:
    Rebecca Kathryn McHugh
  • 依托单位:
Affective and Inflammatory Reactivity to Pain in Opioid Use Disorder
  • 批准号:
    10227188
  • 项目类别:
  • 资助金额:
    $35.22万
  • 财政年份:
    2019
  • 负责人:
    Rebecca Kathryn McHugh
  • 依托单位:
Affective and Inflammatory Reactivity to Pain in Opioid Use Disorder
  • 批准号:
    10025589
  • 项目类别:
  • 资助金额:
    $35.45万
  • 财政年份:
    2019
  • 负责人:
    Rebecca Kathryn McHugh
  • 依托单位:
Affective and Inflammatory Reactivity to Pain in Opioid Use Disorder
  • 批准号:
    10454420
  • 项目类别:
  • 资助金额:
    $35.22万
  • 财政年份:
    2019
  • 负责人:
    Rebecca Kathryn McHugh
  • 依托单位:
国内基金
海外基金
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
  • 批准号:
    JCZRQN202500010
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
  • 依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
  • 批准号:
    2025JJ70209
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
    雷芬芳
  • 依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
  • 批准号:
    --
  • 项目类别:
    面上项目
  • 资助金额:
    --
  • 批准年份:
    2024
  • 负责人:
    万荣
  • 依托单位: